Depakine (Valproate) is an acidic organic compound that has found clinical use as an anticonvulsant and mood-stabilizing drug, primarily in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
Depakine has been approved by US Food and Drug Administration (FDA) and is one of the most effective treatments in controlling preventive treatment of migraine and holds a special place for treating patients suffering from this ailment, said director of the Iranian Headache Association Dr. Ehsasn Mohammadiani-Nejad.
“The foreign version of Depakine has long dominated the Iranian medicine market, but fortunately Iran can now produce Depakine and make it easily available to people. This high-quality medicine is also very cost-efficient compared to its foreign version,” said Mohammadiani-Nejad.
He added that with the production of Depakine, the country will become self-sufficient and have no need to import this medicine.
According to global statistics, 18 percent of women and 6 percent of men suffer from migraine, which makes an average of 12 percent of people in Iran suffering from this ailment.
Add new comment